CCI study looks at risks for patients with diabetes treated with PCI

09/23/2013 | Healio

Diabetes patients who underwent PCI for STEMI had nearly four times the mortality rate of patients who did not have diabetes, according to results from the INFUSE-AMI trial published in Catheterization and Cardiovascular Interventions. Study participants with diabetes had more extensive left anterior descending artery disease, more comorbidities and a 30-day mortality rate of 8.1%, compared with 2.3% among the group without diabetes. The 30-day revascularization rate was 6.4% for diabetes patients compared with 1% for non-diabetes patients.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA